ID   TE-11
AC   CVCL_1761
SY   TE11; Te11
DR   CLO; CLO_0051373
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472004
DR   BioSample; SAMN10988291
DR   cancercelllines; CVCL_1761
DR   CCRID; 3101HUMTCHu91
DR   Cell_Model_Passport; SIDM00348
DR   CGH-DB; 314-1
DR   CGH-DB; 9263-4
DR   ChEMBL-Cells; CHEMBL3308219
DR   ChEMBL-Targets; CHEMBL2366166
DR   Cosmic; 735827
DR   Cosmic; 923180
DR   Cosmic; 926107
DR   Cosmic; 946354
DR   Cosmic; 947599
DR   Cosmic; 1043233
DR   Cosmic; 1123328
DR   Cosmic; 1571761
DR   Cosmic; 2698426
DR   Cosmic-CLP; 946354
DR   DepMap; ACH-000488
DR   EGA; EGAS00001000978
DR   GDSC; 946354
DR   GEO; GSM887692
DR   GEO; GSM888785
DR   GEO; GSM1670530
DR   IARC_TP53; 21663
DR   LiGeA; CCLE_167
DR   LINCS_LDP; LCL-1566
DR   PharmacoDB; TE11_1577_2019
DR   PRIDE; PXD002486
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1761
DR   PubChem_Cell_line; CVCL_1761
DR   RCB; RCB2100
DR   TKG; TKG 0262
DR   Wikidata; Q54972009
RX   PubMed=7732013;
RX   PubMed=8509434;
RX   PubMed=9023415;
RX   PubMed=9096669;
RX   PubMed=9178645;
RX   PubMed=9290701;
RX   PubMed=10741724;
RX   PubMed=11115554;
RX   PubMed=15172977;
RX   PubMed=17804709;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Japanese.
CC   HLA typing: A*24:02,26:01; C*14:01 (PubMed=9178645).
CC   HLA typing: A*24:02,24:02; B*51:01,51:01; C*03:04,03:04; DQB1*06:07,06:07 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Leu (c.329G>T); ClinVar=VCV000406597; Zygosity=Unspecified (PubMed=7732013; PubMed=10741724).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=89.62%; East Asian, South=10.38%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
ST   Source(s): Cosmic-CLP; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 9,12
ST   D13S317: 10
ST   D16S539: 10,11
ST   D5S818: 8,14
ST   D7S820: 11,12
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 17,18
DI   NCIt; C4024; Esophageal squamous cell carcinoma
DI   ORDO; Orphanet_99977; Squamous cell carcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 38
//
RX   PubMed=7732013; DOI=10.1073/pnas.92.9.3963;
RA   Flaman J.-M., Frebourg T., Moreau V., Charbonnier F., Martin C.,
RA   Chappuis P., Sappino A.-P., Limacher J.-M., Bron L., Benhattar J.,
RA   Tada M., Van Meir E.G., Estreicher A., Iggo R.D.;
RT   "A simple p53 functional assay for screening cell lines, blood, and
RT   tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:3963-3967(1995).
//
RX   PubMed=8509434; DOI=10.1007/BF01215923;
RA   Nishihira T., Hashimoto Y., Katayama M., Mori S., Kuroki T.;
RT   "Molecular and cellular features of esophageal cancer cells.";
RL   J. Cancer Res. Clin. Oncol. 119:441-449(1993).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9096669; DOI=10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4;
RA   Barnas C., Martel-Planche G., Furukawa Y., Hollstein M., Montesano R.,
RA   Hainaut P.;
RT   "Inactivation of the p53 protein in cell lines derived from human
RT   esophageal cancers.";
RL   Int. J. Cancer 71:79-87(1997).
//
RX   PubMed=9178645; DOI=10.1006/cimm.1997.1108;
RA   Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M.,
RA   Itoh K.;
RT   "CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with
RT   hepatocellular carcinoma.";
RL   Cell. Immunol. 177:176-181(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=10741724;
RA   Eura M., Chikamatsu K., Katsura F., Obata A., Sobao Y., Takiguchi M.,
RA   Song Y.-S., Appella E., Whiteside T.L., DeLeo A.B.;
RT   "A wild-type sequence p53 peptide presented by HLA-A24 induces
RT   cytotoxic T lymphocytes that recognize squamous cell carcinomas of the
RT   head and neck.";
RL   Clin. Cancer Res. 6:979-986(2000).
//
RX   PubMed=11115554; DOI=10.3892/ijo.18.1.157;
RA   Fujii T., Kato S., Yamana H., Tanaka Y., Fujita H., Shirouzu K.,
RA   Morimatsu M.;
RT   "Expression of G1 cell cycle markers and the effect of
RT   adenovirus-mediated overexpression of p21Waf-1 in squamous cell
RT   carcinoma of the esophagus.";
RL   Int. J. Oncol. 18:157-163(2001).
//
RX   PubMed=15172977; DOI=10.1158/0008-5472.CAN-04-0172;
RA   Sonoda I., Imoto I., Inoue J., Shibata T., Shimada Y., Chin K.,
RA   Imamura M., Amagasa T., Gray J.W., Hirohashi S., Inazawa J.;
RT   "Frequent silencing of low density lipoprotein receptor-related
RT   protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in
RT   esophageal squamous cell carcinoma.";
RL   Cancer Res. 64:3741-3747(2004).
//
RX   PubMed=17804709; DOI=10.1158/0008-5472.CAN-07-2064;
RA   Boonstra J.J., van der Velden A.W., Beerens E.C.W., van Marion R.,
RA   Morita-Fujimura Y., Matsui Y., Nishihira T., Tselepis C., Hainaut P.,
RA   Lowe A.W., Beverloo H.B., van Dekken H., Tilanus H.W., Dinjens W.N.M.;
RT   "Mistaken identity of widely used esophageal adenocarcinoma cell line
RT   TE-7.";
RL   Cancer Res. 67:7996-8001(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//